EXCLUSIVE DISTRIBUTION and LICENSING AGREEMENTExclusive Distribution and Licensing Agreement • December 13th, 2021 • Boon Industries, Inc. • Miscellaneous chemical products • California
THIS AGREEMENT is made and effective as of May 13, 2020 (the “effective date”) by and between C Group LLC, a California Limited Liability Company (hereinafter referred to as “Supplier”), and Boon Industries Inc., an Oklahoma Corporation (hereinafter referred to as “Exclusive Distributor”).
ContractExclusive Distribution and Licensing Agreement • November 12th, 2013
Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin, currently in development for treatment of anorexia-cachexia syndrome related to non-small cell lung cancer in top EU markets
EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT ---------------------------------------------- 1. PARTIES: A. Agro Comercial Fumageira, S.A. and Suerdieck Charutos e Cigarrilhas Ltda., respectively, a corporation and a limited liability company...Exclusive Distribution and Licensing Agreement • December 21st, 1998 • International Cigar Holdings Inc • Florida
Exclusive Distribution and Licensing AgreementExclusive Distribution and Licensing Agreement • July 27th, 2017 • OphthaliX, Inc. • Pharmaceutical preparations
RESDEVCO owns and possesses certain valuable intellectual property, Licensed Technology, Patents, Know-how and formulations and information with regard to a Finished Product, all as defined in Appendices and is the sole owner of all rights interest and title in such Lincensed Technology and the Finished Product and its Patents, Knowhow formulations and information. RESDEVCO is entitled to license its Know-how.
PORTIONS OF THIS AGREEMENT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934; [***] DENOTES OMISSIONSExclusive Distribution and Licensing Agreement • March 29th, 2018 • Wize Pharma, Inc. • Pharmaceutical preparations
This Third Amendment (the “Third Amendment”) is entered into on December 26, 2017 (the “Effective Date”), by and between Resdevco Research and Development Company Ltd., reg. no. 510422223 (the “Licensor”) and Wize Pharma Ltd., reg. no. 520033259, the former name of which is Star Night Technologies Ltd. (the “Licensee”) (the Licensor and the Licensee shall be collectively referred to hereinafter as the “Parties”).
AMENDMENT NO. 2 TO EXCLUSIVE DISTRIBUTION AND LICENSING AGREEMENT BETWEEN WIZE PHARMA LTD. (FORMERLY STAR NIGHT TECHNOLOGIES LTD) AND RESDEVCO LTD.Exclusive Distribution and Licensing Agreement • July 27th, 2017 • OphthaliX, Inc. • Pharmaceutical preparations
This Amendment (the “Amendment”) refers to the Exclusive Distribution and Licensing Agreement between Wize Pharma Ltd. ( the “Licensee”) and Resdevco Ltd. (the “Licensor”) signed on, May 1, 2015 as amended on November 22, 2015 (the “Agreement”) and is entered into on the Execution Date (us defined below).
Appendix F to Exclusive Distribution and Licensing Agreement” between Resdevco Ltd. and Wize Pharma signed on May 1, 2015. This appendix replaces the document of the same name dated July 1, 2017Exclusive Distribution and Licensing Agreement • July 27th, 2017 • OphthaliX, Inc. • Pharmaceutical preparations
